Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 10/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | THRA | P10827 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14484723 | 0.83 | PCNA (0.51) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL14485257 | 0.82 | PCNA (0.61) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL3790720 | 0.79 | ALOX5 (0.48) | POLBTUBB1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL12642750 | 0.78 | PCNA (0.74) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL16124500 | 0.77 | SMN1; SMN2 (0.48) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL14485284 | 0.77 | HPGD (0.51) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL1446362 | 0.74 | ALOX5 (0.50) | PDE4DKMT2AMEN1 | |
| SCHEMBL13949733 | 0.72 | PCNA (0.52) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL14485308 | 0.71 | PCNA (0.77) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL5024604 | 0.70 | TUBB4A (0.50) | PCNAPOLBTHRATHRBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2013006734-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | MKI67, PCNA, PCLAF | PCNA 2/4885POLB 300/4885THRA 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.